Pure Global
NCT04772261

GEBT Lot-to-Lot and Biological Variability

13C-Spirulina Breath Test (13C-GEBT) Lot-to-Lot and Biological Variability Study
Cairn Diagnostics·ClinicalTrials.gov·diagnostic testCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Gastroparesis
Drug/Device/Intervention
13C-Spirulina GEBT
Study type
Interventional
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
Cairn Diagnostics
Location
Brentwood, United States of America
Timeline & enrollment
Phase
N/A
Start date
Feb 05, 2021
End date
Jan 10, 2022
Enrollment
21 participants
Primary outcome

Lot to Lot Variability,Lot to Lot Variability,Lot to Lot Variability,Biological Variability,Biological Variability

Summary

The purpose of this study is to collect information regarding lot-to-lot variability in
 13C-Spirulina test meal lets and within-subject biological variability.

ICD-10 classifications
Attention to gastrostomyGastrostomy statusOther gastritisGastritis, unspecifiedGastric diverticulum
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04772261
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04772261 through Pure Global AI's free database. This phase not specified trial is sponsored by Cairn Diagnostics and is currently Completed. The study focuses on Gastroparesis. Target enrollment is 21 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.